{"id":494213,"date":"2024-04-16T00:55:29","date_gmt":"2024-04-16T07:55:29","guid":{"rendered":"https:\/\/nai500.com\/blog\/2024\/04\/2024%e5%b9%b4%e7%b2%be%e9%80%897%e5%8f%aa%e7%be%8e%e8%82%a1%e7%b3%96%e5%b0%bf%e7%97%85%e5%92%8c%e5%87%8f%e8%82%a5%e8%8d%af%e8%82%a1%e7%a5%a8\/"},"modified":"2024-04-16T00:55:48","modified_gmt":"2024-04-16T07:55:48","slug":"2024%e5%b9%b4%e7%b2%be%e9%81%b87%e5%8f%aa%e7%be%8e%e8%82%a1%e7%b3%96%e5%b0%bf%e7%97%85%e5%92%8c%e6%b8%9b%e8%82%a5%e8%97%a5%e8%82%a1%e7%a5%a8","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hant\/blog\/2024\/04\/2024%e5%b9%b4%e7%b2%be%e9%81%b87%e5%8f%aa%e7%be%8e%e8%82%a1%e7%b3%96%e5%b0%bf%e7%97%85%e5%92%8c%e6%b8%9b%e8%82%a5%e8%97%a5%e8%82%a1%e7%a5%a8\/","title":{"rendered":"2024\u5e74\u7cbe\u90787\u53ea\u7f8e\u80a1\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u85e5\u80a1\u7968"},"content":{"rendered":"<p>\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u8655\u65b9\u85e5\u5e02\u5834\u4e26\u672a\u986f\u73fe\u51fa\u6e1b\u901f\u7684\u8de1\u8c61\u3002Iqvia Institute\u76842024\u5e74\u5168\u7403\u7528\u85e5\u5831\u544a\u986f\u793a\uff0c\u5168\u7403\u80a5\u80d6\u75c7\u652f\u51fa\u57282023\u5e74\u9054\u5230\u4e86240\u5104\u7f8e\u5143\uff0c\u662f2021\u5e74\u76847\u500d\u3002\u6b64\u5916\uff0c2024-2028\u5e74\u671f\u9593\uff0c\u9019\u500b\u5e02\u5834\u7684\u5e74\u8907\u5408\u589e\u9577\u7387\uff08CAGR\uff09\u5c07\u572824%\u81f327%\u4e4b\u9593\uff0c\u5e02\u5834\u898f\u6a21\u9810\u8a08\u52302028\u5e74\u5c07\u9054\u52301310\u5104\u7f8e\u5143\u3002<\/p>\n<p>\u985e\u4f3cWegovy\u7b49GLP-1\u53d7\u9ad4\u6fc0\u52d5\u5291\u7684\u6e1b\u80a5\u6548\u679c\u9ad8\u905410%\u81f315%\uff0c\u65b0\u578b\u6e1b\u80a5\u85e5\u7684\u5d1b\u8d77\u6fc0\u767c\u4e86\u9019\u500b\u9818\u57df\u7684\u7814\u767c\u71b1\u60c5\uff0c\u8afe\u548c\u8afe\u5fb7\u548c\u79ae\u4f86\u90fd\u5df2\u6295\u5165\u4e86\u6578\u5341\u5104\u7f8e\u570b\u7684\u7814\u767c\u8cbb\u7528\u3002\u4e0d\u904e\uff0c\u60f3\u8981\u9810\u6e2c\u672a\u4f86\u5e7e\u5e74\u8ab0\u5c07\u7814\u767c\u51fa\u6700\u6709\u6548\u4e14\u6700\u5b89\u5168\u7684\u6e1b\u80a5\u85e5\uff0c\u9019\u662f\u5e7e\u4e4e\u4e0d\u53ef\u80fd\u5b8c\u6210\u7684\u4efb\u52d9\uff0c\u9019\u4e5f\u52a0\u5927\u4e86\u6295\u8cc7\u8005\u7684\u9078\u80a1\u96e3\u5ea6\u3002<\/p>\n<p>\u4ee5\u4e0b\u662f2024\u5e74\u76847\u53ea\u7cbe\u9078\u7f8e\u80a1\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u85e5\u80a1\u7968\uff1a<\/p>\n<table width=\"561\">\n<tbody>\n<tr>\n<td><strong>\u80a1\u7968<\/strong><\/td>\n<td><strong>\u4eca\u5e74\u8fc4\u4eca\u6536\u76ca\u7387<\/strong><\/td>\n<td><strong>\u96b1\u542b\u80a1\u50f9\u4e0a\u6f32\u6f5b\u529b<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Novo Nordisk A\/S (ticker:\u00a0NVO)<\/td>\n<td>21.6%<\/td>\n<td>2.5%<\/td>\n<\/tr>\n<tr>\n<td>Eli Lilly &amp; Co. (LLY)<\/td>\n<td>30.1%<\/td>\n<td>12.2%<\/td>\n<\/tr>\n<tr>\n<td>Amgen Inc. (AMGN)<\/td>\n<td>-5.4%<\/td>\n<td>18.4%<\/td>\n<\/tr>\n<tr>\n<td>Pfizer Inc. (PFE)<\/td>\n<td>-5.6%<\/td>\n<td>17.4%<\/td>\n<\/tr>\n<tr>\n<td>Viking Therapeutics Inc. (VKTX)<\/td>\n<td>291.3%<\/td>\n<td>55.8%<\/td>\n<\/tr>\n<tr>\n<td>Structure Therapeutics Inc. (GPCR)<\/td>\n<td>2.6%<\/td>\n<td>96.7%<\/td>\n<\/tr>\n<tr>\n<td>Roche Holding AG (OTC: RHHBY)<\/td>\n<td>-11.8%<\/td>\n<td>23.9%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\u8afe\u548c\u8afe\u5fb7<\/h2>\n<p>\u4e39\u9ea5\u88fd\u85e5\u5546<a href=\"https:\/\/nai500.com\/zh-hans\/%e8%82%a1%e7%a5%a8%e6%9f%a5%e8%af%a2\/?qm_symbol=NVO\">\u8afe\u548c\u8afe\u5fb7Novo Nordisk\uff08NYSE:NVO\uff09<\/a>\u662f\u6e1b\u80a5\u85e5\u5e02\u5834\u7684\u9738\u4e3b\uff0c\u5e02\u5834\u4efd\u984d\u9ad8\u905460%\u30022023\u5e74\uff0c\u8a72\u516c\u53f8\u7684\u80a5\u80d6\u75c7\u548c\u7cd6\u5c3f\u75c5\u85e5\u7269\u6536\u5165\uff08\u5305\u62ecOzempic\u548cWegovy\uff09\u7e3d\u8a08312\u5104\u7f8e\u5143\uff0c\u5360\u5176\u7e3d\u6536\u5165\u7684\u5927\u7d0490%\u30024\u6708\u521d\uff0c\u8afe\u548c\u8afe\u5fb7\u767c\u4f48\u6709\u95dc\u6e1b\u91cd\u85e5\u7269Wegovy\uff08\u53f8\u7f8e\u683c\u9b6f\u80bd\u7684\u5546\u54c1\u540d\uff09\u7684\u91cd\u8981\u6d88\u606f\u3002\u6700\u65b0\u7814\u7a76\u986f\u793a\uff0c\u8a72\u85e5\u7269\u589e\u5f37\u4e86\u8ddf\u80a5\u80d6\u75c7\u76f8\u95dc\u7684\u5fc3\u529b\u8870\u7aed\u548c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u7684\u7684\u6e1b\u91cd\u6548\u679c\uff0c\u6e1b\u8f15\u4e86\u75c7\u72c0\u4e26\u4e14\u653e\u5bec\u4e86\u8eab\u9ad4\u9650\u5236\u3002<\/p>\n<h2>\u79ae\u4f86<\/h2>\n<p>\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5370\u7b2c\u5b89\u7d0d\u6ce2\u5229\u65af\u7684\u79ae\u4f86Eli Lilly and Co\uff08NYSE:LLY\uff09\u8ddfViking Therapeutics\u540c\u8655GLP-1\uff08\u80f0\u9ad8\u8840\u7cd6\u7d20\u6a23\u80bd-1\uff09\u8cfd\u9053\uff0c\u516c\u53f8\u65d7\u4e0b\u6709\u5169\u6b3e\u66a2\u92b7\u7522\u54c1\uff0c\u5b83\u5011\u5206\u5225\u70ba\u6e1b\u80a5\u85e5Zepbound\u4ee5\u53ca\u964d\u7cd6\u85e5Mounjaro\u3002Zepbound\u73fe\u5728\u88ab\u6436\u8cfc\u4e00\u7a7a\uff0c\u800cMounjaro\u9810\u8a08\u5c07\u52a9\u529b\u516c\u53f8\u6536\u5165\u5f9e2023\u5e74\u7684341\u5104\u7f8e\u5143\u589e\u81f32024\u5e74\u7684404-416\u5104\u7f8e\u5143\u3002\u6b64\u5916\uff0c\u79ae\u4f862023\u5e74\u4ee5\u4f86\u5df2\u7d93\u5c07\u80a1\u606f\u7ffb\u500d\uff0c\u76ee\u524d\u7684\u9060\u671f\u80a1\u606f\u7387\u70ba0.7%\u3002<\/p>\n<h2>\u5b89\u9032<\/h2>\n<p>\u76f8\u6bd4\u79ae\u4f86\u548c\u8afe\u548c\u8afe\u5fb7\uff0c\u5b89\u9032Amgen\uff08NASDAQ:AMGN\uff09\u662f\u6e1b\u80a5\u85e5\u5e02\u5834\u4e0a\u7684\u5f8c\u4f86\u8005\uff0c\u516c\u53f8\u6ce8\u5c04\u578b\u80a5\u80d6\u75c7\u85e5\u7269MariTide\u8ddd\u96e2\u4e0a\u5e02\u4e5f\u9084\u6709\u5f88\u9577\u7684\u8ddd\u96e2\u3002MariTide\u7684\u4e00\u671f\u8a66\u9a57\u7d50\u679c\u986f\u793a\uff0c\u53d7\u8a66\u8005\u7528\u85e53\u500b\u6708\u4e4b\u5f8c\u5e73\u5747\u6e1b\u91cd14.5%\uff0c\u800c\u4e14\u66f4\u70ba\u91cd\u8981\u7684\u662f\uff0c\u6700\u5f8c\u4e00\u6b21\u7d66\u85e5\u5f8c\u7684\u7b2c150\u5929\u6e1b\u91cd\u4f9d\u7136\u7dad\u6301\u572811.2%\u3002\u4e8c\u671f\u8a66\u9a57\u5df2\u7d93\u5728\u9032\u884c\u4e2d\uff0c\u7d50\u679c\u5c07\u5728\u4eca\u5e74\u665a\u4e9b\u6642\u5019\u516c\u4f48\u3002\u6700\u5f8c\uff0c\u5b89\u9032\u80a1\u7968\u7684\u80a1\u606f\u7387\u9ad8\u90543.3%\u3002<\/p>\n<h2>\u8f1d\u745e\u88fd\u85e5<\/h2>\n<p>\u7e3d\u90e8\u4f4d\u65bc\u7d10\u7d04\u7684\u8f1d\u745e\u88fd\u85e5Pfizer\uff08NYSE:PFE\uff09\u651cdanuglipron\u9032\u8ecd\u6e1b\u80a5\u85e5\u5e02\u5834\uff0c\u4f46\u7d50\u679c\u4e26\u4e0d\u7406\u60f3\uff0c\u539f\u56e0\u662f\u9019\u6b3e\u53e3\u670dGLP-1R\u6fc0\u52d5\u5291\u5728\u8a66\u9a57\u4e2d\u6703\u5f15\u767c\u5641\u5fc3\u53ca\u5176\u4ed6\u80c3\u90e8\u554f\u984c\u3002\u4e0d\u904e\uff0c\u8a72\u88fd\u85e5\u5de8\u982d\u7684\u7814\u767c\u548c\u7522\u54c1\u7ba1\u7dda\u975e\u5e38\u8c50\u5bcc\u4e14\u591a\u5143\u5316\uff0c\u9019\u70ba\u516c\u53f8\u91cd\u65b0\u8a08\u5283\u6e1b\u80a5\u85e5\u9805\u76ee\u63d0\u4f9b\u4e86\u6642\u9593\u548c\u8ca1\u52d9\u4e0a\u7684\u652f\u6301\u3002\u6700\u5f8c\uff0c\u8a72\u80a1\u80a1\u606f\u7387\u9ad8\u90546.3%\u3002<\/p>\n<h2>Viking Therapeutics<\/h2>\n<p>\u7e3d\u90e8\u4f4d\u65bc\u52a0\u5229\u798f\u5c3c\u4e9e\u5dde\u8056\u5730\u4e9e\u54e5\u7684Viking Therapeutics Inc\uff08NASDAQ:VKTX\uff09\u958b\u767c\u7684\u662fGLP-1\u548cGIP\uff08\u8461\u8404\u7cd6\u4f9d\u8cf4\u6027\u4fc3\u80f0\u5cf6\u7d20\u91cb\u653e\u591a\u80bd\uff09\u85e5\u7269\uff0c\u4e26\u4e14\u5230\u76ee\u524d\u70ba\u6b62\u8a66\u9a57\u7d50\u679c\u90fd\u9084\u4e0d\u932f\u3002\u6700\u8fd1\uff0cViking\u5831\u544a\u4e86\u53e3\u670d\u6e1b\u80a5\u85e5VK2735\u4e00\u671f\u8a66\u9a57\u7684\u7a4d\u6975\u6578\u64da\uff0c40\u6beb\u514b\u5291\u91cf\u7d44\u60a3\u800528\u5929\u7684\u5b89\u6170\u5291\u8abf\u6574\u5e73\u5747\u6e1b\u91cd3.3%\uff0c\u6c92\u6709\u5831\u544a\u526f\u4f5c\u7528\u3002\u6b64\u5916\uff0cVK2735\u6ce8\u5c04\u5291\u7684\u60a3\u8005\u5728\u7528\u85e513\u5468\u5f8c\u5e73\u5747\u6e1b\u91cd13.1\u78c5\u3002<\/p>\n<h2>Structure Therapeutics<\/h2>\n<p>\u7e3d\u90e8\u4f4d\u65bc\u820a\u91d1\u5c71\u7684Structure Therapeutics Inc.\uff08NYSE: GPCR\uff09\u958b\u767c\u7684\u53e3\u670d\u6e1b\u80a5\u85e5GSBR-1290\u4e5f\u662f\u9776\u5411GLP-1\u53d7\u9ad4\u300212\u6708\u7684\u5831\u544a\u986f\u793a\uff0cGSBR-1290\u7684\u8a66\u9a57\u7d50\u679c\u96d6\u7136\u4e0d\u53ca\u5e02\u5834\u9810\u671f\uff0c\u4f468\u5468\u5f8c\u7684\u5b89\u6170\u5291\u8abf\u6574\u5f8c\u5e73\u5747\u6e1b\u91cd4.7%\u3002\u6e1b\u91cd\u548c\u7cd6\u5c3f\u75c5\u7684\u4e8c\u671f\u8a66\u9a57\u5c07\u65bc\u4eca\u5e74\u665a\u4e9b\u6642\u5019\u555f\u52d5\u3002<\/p>\n<h2>\u7f85\u6c0f\u63a7\u80a1<\/h2>\n<p>\u7e3d\u90e8\u4f4d\u65bc\u745e\u58eb\u5df4\u585e\u723e\u7684\u7f85\u6c0f\u63a7\u80a1Roche Holding\uff08NASDAQOTH:RHHBY\uff09\u6700\u8fd1\u6536\u8cfc\u79c1\u4eba\u751f\u547d\u79d1\u5b78\u516c\u53f8Carmot Therapeutics\u3002Carmot\u6b63\u5728\u958b\u767c3\u6b3e\u81e8\u5e8a\u968e\u6bb5\u7684\u57fa\u65bc\u8178\u4fc3\u80f0\u5cf6\u7d20\u7684\u80a5\u80d6\u75c7\u548c\u7cd6\u5c3f\u75c5\u7642\u6cd5\uff0c\u5176\u4e2d2\u6b3e\u7684\u4e8c\u671f\u8a66\u9a57\u7d50\u679c\u7a4d\u6975\u3002\u6b64\u5916\uff0c\u8a72\u80a1\u76ee\u524d\u80a1\u606f\u73874.5%\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u8655\u65b9\u85e5\u5e02\u5834\u4e26\u672a\u986f\u73fe\u51fa\u6e1b\u901f\u7684\u8de1\u8c61\u3002Iqvia Institute\u76842024\u5e74\u5168\u7403\u7528\u85e5\u5831\u544a\u986f\u793a\uff0c\u5168\u7403\u80a5 [&hellip;]<\/p>\n","protected":false},"author":27,"featured_media":494211,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1522,431],"tags":[2156,927,2001,564],"class_list":["post-494213","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1522","category-trends-strategies-zh-hant","tag-2156","tag-927","tag--zh-hant","tag-564","sectors-life-science-zh-hant","locations-europe-zh-hant","locations-us-zh-hant","exchange-nasdaq-zh-hant","exchange-nyse-zh-hant"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/494213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=494213"}],"version-history":[{"count":3,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/494213\/revisions"}],"predecessor-version":[{"id":494216,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/494213\/revisions\/494216"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media\/494211"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=494213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=494213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=494213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}